INTRODUCTION: To diagnose rectal cancer and monitor treatment response after preoperative concurrent chemoradiotherapy (CCRT) in rectal cancer patients using proton-1 magnetic resonance spectroscopy ((1)H-MRS). MATERIALS AND METHODS: We enrolled 134 rectal cancer patients before treatment, of whom 34 underwent preoperative CCRT and follow-up MR spectroscopy before surgery. (1)H-MRS was performed using a six-channel phased-array coil at 3.0 T. We evaluated the presence of a choline peak at 3.2 ppm, and lipid peaks at 0.9 and 1.3 ppm, and glutamine and glutamate peaks at 2.1-2.3 and 2.7 ppm seen at two TEs (40 and 135 ms). We divided MR spectra patterns into two groups (A and B). RESULTS: A choline peak at 3.2 ppm seen in both TEs was characteristic for rectal cancer before treatment. Of 103 patients, 55 (53%) showed an elevated choline peak before treatment (type A). Type A spectra were seen in 68% of patients (23/34) before preoperative CCRT. After CCRT, the choline peak disappeared, resulting in only the lipid peak at 1.3 ppm (type B) in 97% of patients (33/34). DISCUSSION: We optimized a localized in vivo(1)H-MRS method for detection of rectal adenocarcinoma and monitoring treatment response after preoperative CCRT. The method appears to be a promising and feasible noninvasive modality.
INTRODUCTION: To diagnose rectal cancer and monitor treatment response after preoperative concurrent chemoradiotherapy (CCRT) in rectal cancerpatients using proton-1 magnetic resonance spectroscopy ((1)H-MRS). MATERIALS AND METHODS: We enrolled 134 rectal cancerpatients before treatment, of whom 34 underwent preoperative CCRT and follow-up MR spectroscopy before surgery. (1)H-MRS was performed using a six-channel phased-array coil at 3.0 T. We evaluated the presence of a choline peak at 3.2 ppm, and lipid peaks at 0.9 and 1.3 ppm, and glutamine and glutamate peaks at 2.1-2.3 and 2.7 ppm seen at two TEs (40 and 135 ms). We divided MR spectra patterns into two groups (A and B). RESULTS: A choline peak at 3.2 ppm seen in both TEs was characteristic for rectal cancer before treatment. Of 103 patients, 55 (53%) showed an elevated choline peak before treatment (type A). Type A spectra were seen in 68% of patients (23/34) before preoperative CCRT. After CCRT, the choline peak disappeared, resulting in only the lipid peak at 1.3 ppm (type B) in 97% of patients (33/34). DISCUSSION: We optimized a localized in vivo(1)H-MRS method for detection of rectal adenocarcinoma and monitoring treatment response after preoperative CCRT. The method appears to be a promising and feasible noninvasive modality.
Authors: Roberto García-Figueiras; Sandra Baleato-González; Anwar R Padhani; Laura Oleaga; Joan C Vilanova; Antonio Luna; Juan Carlos Cobas Gómez Journal: Diagn Interv Radiol Date: 2016 Jan-Feb Impact factor: 2.630
Authors: Ping Wang; Byunghee Yoo; Sarah Sherman; Pinku Mukherjee; Alana Ross; Pamela Pantazopoulos; Victoria Petkova; Christian Farrar; Zdravka Medarova; Anna Moore Journal: Int J Cancer Date: 2016-04-15 Impact factor: 7.396
Authors: Roberto García-Figueiras; Sandra Baleato-González; Anwar R Padhani; Ana Marhuenda; Antonio Luna; Lidia Alcalá; Ana Carballo-Castro; Ana Álvarez-Castro Journal: Insights Imaging Date: 2016-04-30